Third Harmonic Bio
Clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. Learn more
Launch date
Employees
Market cap
AUD862m
Enterprise valuation
AUD473m (Public information from Sep 2024)
Share price
$14.73 THRD
Cambridge Massachusetts (HQ)
Authorizing premium user...